Abstract
There are more than 70 different sleep disorders but the most common ones
include insomnia, sleep apnea, restless legs syndrome, and narcolepsy. One of
the fastest growing sector in the sleep disorder treatment market is
obstructive sleep apnea (OSA) products. OSA affects up to 18 million patients
in the US with as many as 85% are undiagnosed. Similarly, 30 million are
chronic sufferers of insomnia but only a third of chronic sufferers are
receiving treatment. A key reason for this low percentage of people receiving
treatment is the side effects associated with most of the insomnia drugs. Over
1.6 million Americans use some form of alternative medicine to treat insomnia.
With rising awareness of sleep disorders, more people are undergoing tests to
understand the basics of their sleep disorder condition. Hospitals are opening
new sleep centers and upgrading old ones. Patients are looking at innovative
aspects in sleep centers which make them feel more homely.
Pharma companies are coming up with new sleeping disorder drugs. Gamma
Aminobutyric Acid (GABA) agents dominate the insomnia market. More than a
dozen insomnia drugs are in phase II and phase III clinical trials. Major
products are Ambien, Ambien CR, Lunesta, Temazepam, and Zolpidem. Respironics
and ResMed are the leading competitors in the continuous positive airway
pressure (CPAP) market.
The report analyzes the sleep disorder treatment market. The focus is on OSA
and insomnia treatment products. The report also profiles the major companies,
with a discussion of their key business strategies. It also analyzes the major
market and demographic trends prevalent in the sleep disorder treatment market.
View Cart
